Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAXIS
NCT06782373Phase 2Recruiting
- Sponsor
- Sobi
- Start
- May 2025
- Primary completion
- Dec 2026
- Countries
- 8
01
Overview
A Phase 2 trial of pacritinib in VEXAS syndrome (VEXAS), sponsored by Sobi. Started May 2025; status: recruiting.
02
Drugs
pacritinib
03
Conditions
VEXAS syndrome (VEXAS)
Beyond the preview
Go deeper on NCT06782373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782373.